This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The negotiation, informed by confidential data from manufacturers and analysis by the Centers for Medicare and Medicaid Services, will result in a maximum fair price for each drug, which will be announced Sept. 1, 2024, and will take effect Jan. billion in the first year and more than $98 billion by 2031.
A few recent examples make the point: A New York Times story in June 2024 bore the headline, “Pharmacy benefit managers are driving up drug costs for millions of people, employers and the government.” That view is wrong. Read the rest…
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies. Continue to STAT+ to read the full story…
Blue Shield of California, a health insurance company that covers almost 5 million people, is restructuring how it will pay for prescription drugs by dividing the work up among five different vendors — two of which include Amazon and Mark Cuban’s pharmacy company.
STAT’s taking a look at some of the recent health policy trends that states will start to implement in 2024. For most states, the new year means a new legislative session.
In May 2024 , nearly 90% of pharmacies were closed for a day as thousands of pharmacists protested over “over drug shortages, pharmacy closures and fears medications could be sold online, as well as higher pay.”
On 2024 guidance, Merck said it expects sales in the range of $62.7-$64.2 Biotech can’t shake the Fed The XBI, a closely watched index of biotech stocks, turned red for the year yesterday, and not because of a clinical disappointment, a drugpricing scandal, or an M&A rumor that came to nothing.
Thanks to the IRA, Part D Plans Will Prefer High-List, High-Rebate Drugs. Click here to see the original post from January 2024. It's time for Drug Channels ’ annual reality check on U.S. drugpricing. For 2023, brand-name drugs’ list prices again grew at mid-single-digit rates.
The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drugprices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election.
In this issue: An update on the retail pharmacy shakeout Arguing for high drugprices A leading researcher provides a 340B reality check Physicians don’t want pharmacists getting uppity Plus, Dave Grohl fights for your right to…have healthcare price transparency? Sorry, no Threads.) All rights reserved.
Medicare and Medicaid are facing a familiar quandary: how to provide coverage for new weight loss drugs with price tags that could effectively bankrupt the federal government’s health care budget while simultaneously ensuring continuous coverage for all other health care services used by millions of Americans.
Amylyx did not immediately disclose how much it will charge for Relyvrio, but the company is conducting a larger, longer clinical trial to confirm the benefits, with data expected in late 2023 or early 2024. In a rare commitment, the company has promised to remove the drug from the market if that study is not successful.
Unfortunately, the current drugpricing bill fails to take a holistic approach to addressing a system that drives affordability challenges for patients. The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.
By doing so, the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based on when the drug first goes on the market. Novo Nordisk will continue to restrict U.S. demand , STAT notes. The
According to results from a survey by GlobalData, the top challenges for the pharmaceutical industry in 2024 will be inflation, geopolitical conflict and drugpricing pressures. Data outcomes revealed that most respondents from Pharma considered that drugpricing and reimbursement constraints will have a negative impact in 2024.
JPM Week is finally drawing to a close, sending the drug industry’s many financiers scattering from San Francisco to their respective homes and ski destinations. In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout.
Comments may be submitted here until April 30, 2024. UPCOMING EVENTS WHO 78th INN Consultation Geneva, Switzerland – March 19, 2024 ASCO Annual Meeting Chicago, IL – May 31-June 4, 2024 BIO International Meeting San Diego, CA – June 3-6, 2024 DIA Global Annual Meeting San Diego, CA – June 16-20, 2024
It's time for Drug Channels ’ annual reality check on U.S. drugpricing. For 2023, brand-name drugs’ list prices again grew at mid-single-digit rates. However, net prices dropped for an unprecedented sixth consecutive year. Details below.
As another year comes to an end and the world seems to hit the proverbial pause button, the temptation to look ahead is too great to ignore. After all, this is what journalists like to do as the calendar turns another page. So once again, we will take a whack at identifying some of the most noteworthy developments to watch.
I am pleased to announce our new 2024 Economic Report on U.S. Download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) HMP Global’s Drug Channels Institute releases ‘2024 Economic Report on U.S. The 2024 Economic Report on U.S. Read on for some additional details.
On March 19, 2024, Drug Channels Institute will release The 2024 Economic Report on U.S. drugpricing, reimbursement, and dispensing system. prescription drug channels. prescription drug channels. Review pricing/license options and place a preorder. Pharmacies and Pharmacy Benefit Managers.
The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers. Below, I walk through the economic fundamentals to help you understand another obscure aspect of our opaque drugpricing system. to 1:30 p.m.
As Election Day 2024 gets closer, STAT’s First Opinion asked executives from leading biotech and pharmaceutical companies to reflect on how their industry is being portrayed in the presidential campaign — and what their hopes are for a new presidential administration. You
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. This event is part of The Drug Channels 2023 Video Webinar Series. Dr. Adam J.
… Now that Eli Lilly slashed the price for some of its insulin products, the moves raised questions about what will happen to other efforts to provide low-cost insulin, Kaiser Health News explains. And the Mark Cuban Cost Plus Drug Co. But drug=pricing experts predict Lilly’s moves will not undercut those efforts.
Damian here with an in-depth preview of a certain annual biotech conference, a look at the cutting edge of obesity drug development, and year’s first IPO filing. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone.
list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step in response to a years-long outcry over the cost of the diabetes treatments. The company plans to cut the list price of its NovoLog insulin by 75%, and the prices for Novolin and Levemir by 65% starting in January 2024.
Next week, Drug Channels Institute (DCI) will release our 2024 Economic Report on U.S. drugpricing, reimbursement, and dispensing system. We’re offering special discounted pricing if you order before April 7, 2024. Pharmacies and Pharmacy Benefit Managers. For 2023, DCI estimates that U.S. to 1:30 p.m.
Challenging market conditions, driven by drugpricing pressures, regulatory shifts, and geopolitical tensions, have reshaped the landscape, offering both hurdles and opportunities for contract manufacturing organisations (CMOs) to adapt and innovate amidst global generic shortages, reveals GlobalData.
Following the lead of its rivals, Sanofi will cut the price of its most widely prescribed insulin in the U.S. The change comes after Eli Lilly and then Novo Nordisk announced plans this month to reduce list prices for some of their own insulin products by similar amounts. The moves will go into effect on Jan.
Gavin discusses the three key reasons for duplicate discounts between the 340B DrugPricing Program and the Medicaid Drug Rebate Program. To learn more, register for Kalderos’ August 21, 2024, webinar: Revolutionizing Government Discount Programs: Why Traditional Methods Fail. Read on for Gavin’s insights.
f you’re an independent pharmacy owner or pharmacist, you’re probably aware of the upcoming changes to DIR fees that will take effect in 2024. In this blog post, we will discuss the evolution of DIR fees leading up to the DIR fee changes coming in 2024, and the pros and cons independent pharmacies owners should prepare for.
And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drugprices. In reality, nearly all drug spending growth occurred due to growth in the number of people treated, prescriptions dispensed, and other nonprice factors. healthcare expenditures. healthcare expenditures.
WASHINGTON — David Ricks, who leads Eli Lilly, made a major early donation to a super PAC in support of former vice president Mike Pence — one of the first big 2024 donations from a major player in the pharmaceutical industry.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: The 340B DrugPricing Program: Trends, Controversies, and Outlook This event will be broadcast live on Friday, June 21, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.
Informa Connect’s Life Sciences Pricing & Contracting USA May 21-23, 2024 | New Orleans Drug Channels readers save 10% with code 24DRCH10* Whether your daily focus is on Medicaid, Government Pricing, 340B, DrugPrice Transparency, Commercial Contracting or Chargebacks , we have you covered!
It's time for Drug Channels annual examination of U.S. brand-name drugpricing. For 2024, average brand-name drugs list prices grew by only 2.3%. Whats more, after adjusting for overall inflation, brand-name drug net prices dropped for an unprecedented seventh consecutive year.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.
NHC Provides Input on Patient Engagement in Medicare DrugPrice Negotiations September 20, 2024 By: Allen Pinn, Coordinator, Policy August 16 marked two years since the Inflation Reduction Act (IRA) was signed into law. Earlier this year CMS released draft guidance for Initial Payment Applicability Year (IPAY) 2027.
” It’s the final of three phases in the Centers for Medicare and Medicaid Services’ hospital price transparency rollout. The first phase was the original rollout in 2021, followed by an update in July 2024. Continue to STAT+ to read the full story…
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content